Patent ID: 11946928
Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL
Field: Measurement (Instruments)
Classification: CPC G  C | IPC C  G

Claim 2:
3. A method of treating airway dysfunction, the method comprising administering:
a) a chest CT, smoking cessation, and/or avoiding aspiration risk and inhalational injury to a subject determined to have a decreased level of expression of at least one of:
at least one gene of Group A, and at least one gene of Group B; and/or
an increased level of expression of at least one of:
at least one gene of Group C, at least one gene of Group D, and at least one gene of Group E;

b) an immunosuppressant and/or a more aggressive immunosuppressant regimen to a subject who had previously received and lung transplant and was determined to have a decreased level of expression of at least one of:
at least one gene of Group A, and at least one gene of Group B; and/or
an increased level of expression of at least one of:
at least one gene of Group C, at least one gene of Group D, and at least one gene of Group E; or

c) an immunosuppressant and/or a more aggressive immunosuppressant regimen to a subject who had previously received a bone marrow or blood stem cell transplant and was determined to have a decreased level of expression of at least one of:
at least one gene of Group A, and at least one gene of Group B; and/or
an increased level of expression of at least one of:
at least one gene of Group C, at least one gene of Group D, and at least one gene of Group E;

d) an inhibitor of dipeptidyl peptidase 1 (DPP1) to a subject who had previously received a bone marrow or blood stem cell transplant and was determined to have a decreased level of expression of at least one of:
at least one gene of Group A, and at least one gene of Group B; and/or
an increased level of expression of at least one of:
at least one gene of Group C, at least one gene of Group D, and at least one gene of Group E; and/or

e) an inhibitor of DPP1 to a subject who has chronic obstructive pulmonary disease (COPD), asthma, or rheumatoid arthritis and was determined to have a decreased level of expression of at least one of:
at least one gene of Group A, and at least one gene of Group B; and/or
an increased level of expression of at least one of:
at least one gene of Group C, at least one gene of Group D, and at least one gene of Group E; and, wherein a decreased level of expression is decreased relative to the level of the at least one gene in a population of subject who do not have or are not diagnosed as having, and/or do not exhibit signs or symptoms of airway dysfunction, and an increased level of expression is increased relative to the level of the at least one gene in a population of subject who do not have or are not diagnosed as having, and/or do not exhibit signs or symptoms of airway dysfunction;, wherein Group A consists of:
ZNF493; ZNF519; ENSG00000271430; MYH7B; MKRN5P; ENSG00000270574;
VN1R83P; ENSG00000268555; ZNF577; NBPF11; SCUBE2; SGK2; BNIPL;
ENSG00000271533; PCDHGB6; LRP1; PCDHGB7; ENSG00000262877; ABCC5;
PMS2134; TTC28-AS1; PRR24; CD81; RGL3; PTPRS; ENSG00000271011; ZNF286B;
GNB1L; PCDHGA12; SLC16A10; ZNF66; ENSG00000261584; ZNF311; ZNF718;
ENSG00000223745; RAB40A; ENSG00000268119; PCDHGA4; ENSG00000270589;
ENSG00000256142; DLL1; BRAFP1; PCDHGA11; FTX; FLYWCH1; NOVA1;
KANSL1; ZNF826P; ENSG00000196295; ENSG00000229036; TLE3; KLF8; LONRF2;
PCDHGB8P; ENSG00000259326; A0C2; RAPGEFL1; ARL10; ADAMTS10;
ENSG00000250303; TSHZ2; CRYM-AS1; ENSG00000213971; TVP23CP2;
ENSG00000234978; ZBTB12; PCDHGA9; RPS3AP29; KSR2; ENOSF1;
ENSG00000233175; ENSG00000260729; LINC00664; ZNF257; POU5F1P5; FN3K;
ZNF814; CYP2C19; ENSG00000270096; PDE11A; FAM13A-AS1; KCNMA1;
ENSG00000247270; ENSG00000270019; ENSG00000270154; ENSG00000248445;
ENSG00000234129; ENSG00000267169; ENSG00000261423; C1RL-AS1; NONOP2;
SLC26A5; STX18-AS1; AMT; ENSG00000232626; ENSG00000235834; RN7SL648P;
ENSG00000254634; ENSG00000236144; ACAP2-IT1; ENSG00000268472; TDRD6;
ENSG00000272563; SUDS3P1; PCDHGB4; FOX03B; ENSG00000272977;
LINC00176; MY015A; GHRLOS; TTC28; ENSG00000271840; NBPF20; VANGL2;
JMID7-PLA2G4B; ENSG00000267940; OGDHL; ENSG00000206195; KLF11;
TAPT1-AS1; TMEM59L; ACKR3; ENSG00000184441; KAT2A; SULT1A3; SIPA1L2;
RPL5134; CTSF; ZNF208; CYP2E1; L3MBTL1; BENDS; ACACB; ENSG00000261087;
NFATC4; CES4A; ZFP2; BSN; ENSG00000254469; ZNF514; ENSG00000176593;
ENSG00000232116; OTX1; ENSG00000269918; AVIL; ENSG00000271971; MICU3;
GRAMD1A; C1QTNF6; KIF3C; ZACN; RPL7P46; PLA2G4F; SLX1A-SULT1A3;
ZNF135; OR2A9P; TMEM63C; TG; ENSG00000261502; ARL5B-AS1; ZNF705E;
PCDHGC5; GOLGA8A; PLEKH111; PPAP2B; ENSG00000267481; OR7E71P;
ENSG00000259585; ENSG00000225210; TSSK1B; ENSG00000215022; STRC;
ENSG00000250290; UBAP1L; ENSG00000264112; LINC00959; SPATA41; CRYGS;
ZNF862; ENSG00000225032; PCED1B; SMAD6; ENSG00000264538; FRS3;
ENSG00000256139; NSUN5P1; LTB134; ENSG00000267053; ENSG00000171282;
PCDHGA7; GREB1; ADAM1A; ENSG00000251323; ENSG00000271917;
ENSG00000253366; ENSG00000225241; IL11RA; PCDHB18; FAM85A; UPK3BP1;
ACADL; ENSG00000236055; ZNF285; and ENSG00000239665;, wherein Group B consists of:
LRP4; ZNF578; FAT2; FGFR3; MCC; SLC26A9; MKL2; AGKP1; KRT15; CSRNP3;
PKP1; FSTL3; NEURL1; JAG2; DACT2; TRO; NDRG1; ADCY2; IGSF3; NLGN4Y;
SALL2; SUSD4; ARSG; BCL11A; RNF165; TP63; UGT1A7; CACNA1A; PAPPA;
SULF2; RGS17; PIK3R1; SNX31; COL4A5; SNAI2; UGT1A5; SYNGR1;
ENSG00000213963; SV2A; FGFR2; KANK1; WNT5A; FZD7; SRRM3; SEMA5A;
ZNF471; HYKK; PPM1L; ARHGAP28; UGT1A8; ARHGEF10; MT1X; FOXN1;
NTF3; SMOC2; USP44; FBXL16; EPAS1; EGFR; PTPRG; NEB; GDNF-AS1;
FAM117B; RERG; ZBTB47; ADAMTS9-AS2; PAPLN; NCKAP5 STK32A; FAT4;
LGR6; TPTE2P1; SLITRK6; EVPLL; POMGNT1; KCTD15; WSCD1; KIF7; KIF1A;
FRAS1; KRT5 ENSG00000174171; CDH11; ZFP28; GPRASP1; PRKY; COL4A6;
LSAMP; SYDE1; ENSG00000271880; RGMA; BOC; SLC2A9; WNT2B; CDHR1;
ENSG00000248705; TGFB2; NCAM1; LTB4R; TLE2; AP3B2; LRRC2; MEGF6;
RNF212; FBLN1; SLCO4C1; WNT3A; ZNF665; ESYT3; FREM2; ARHGEF4;
LURAP1; SETP21; COL7A1; B4GALNT4; FBN1; ZNF90; LRP1B; ABCC9;
ENSG00000256995; S1PR5; EFS; NPTX1; ENSG00000260197; UGT1A2P; SLC16A2;
MAN1C1; MARVELD1; FGF9; CIB2; LGR5; KIRREL; LTB4R2; SPTB; ITPRIPL1;
PHLDB1; SPRY1; DEPTOR; EPHA4; TTTY10; TET1; ZNF667; EPHB6;
ENSG00000250685; ENSG00000271738; IGFBP4; ARHGEF25; TRPV6; KCNB2;
SPRY2; DLK2; and CLUL1;, wherein Group C consists of:
ENSG00000258545; ENSG00000257512; ASL; CCDCl60; SMIM6; PLCB1;
TMEM125; C20orf201; CD38; ENSG00000268129; TSPAN2; DAPP1; IDH2; APOL4;

HRASLS2; C9orf66; BFSP1; DLG1-AS1; C16orf54; LAMP3; LYSMD2; PSMB9;
NR5A2; ENSG00000005189; COCH; CCDC67; XK; OR7E14P; LINC00589; F5;
PDE3A; RTP4; ENSG00000253474; ANTXR2; HCG4P3; FATE1; FBLN5
ENSG00000259153; NMI; ENSG00000231901; PSMB8 SERF1A; MOCOS; GSTM1;
RAMP1; LINC00643; PRKG1; ENSG00000225335; ENSG00000270659; CNTF;
ENSG00000272463; ENSG00000260552; FHL1; KIF18A; RARRES3; TNFAIP8L3;
PSMB10; ENSG00000227053; DPF1; GSTT2; TMEM176B; RPL7AP64; CDKN2D;
ENSG00000196826; MUC12; ENSG00000260806; GLIPR2; USP18;
ENSG00000238837; C19orf38; ABCC2; VWA5A; SGOL2; PKIB; KLB; TMEM200C;
and SHH;, wherein Group D consists of:
LINC00888; FBX016; SCRN1; ENSG00000259508; LINC00467; MPC2; KIAA0895;
SEPW1; CALML4; ERICH2; SLC51B; FAM69A; ENSG00000259802;
ENSG00000249241; MRPS31; CCDCl76; DUSP14; TMEM17; VIM-AS1; GSTP1;
CCT6B; RUVBL1; ENSG00000267325; AAED1; SLC25A4; Clorf192; DYRK3;
ELK3; ENSG00000272092; LINC00326; B9D2; LINC00240; IFT43; CPNE8; SMIM22;
PHTF1; C11orf70; APOO; SPAG1; CCDC65; DPCD; CCDCl04; RABL5;
ENSG00000263450; DNPH1; ENSG00000234478; ENSG00000233170; LINC01132;
IQCK; ENSG00000257698; ROPN1L; AHSA1; C21orf59; Cl5orf65;
ENSG00000271133; IL7; LXN; DNAL4; C6orf99; MAPS; C1orf189; LINC00948;
DHX40; GFM2; LRRC34; SPA17; ENSG00000261465; C21orf119; TUBA1A; GJB7;
TOMM34; NUDT7; LINC00908; C10orf107; C20orf85; ARL3; DNAL1; CNTN5
MYCBP; ENSG00000266916; ENSG00000260057; CYSTM1; ENSG00000236028;
UFC1; C9orf135; ENSG00000263011; DSTN; IFT57; C9orf116; MORN2; PPIL6;
LCA5L; DPY30; CEP97; AKAP14; ENSG00000272514; CAPSL; CC2D2A; OSCP1;
DYX1C1; PNLDC1; SPATA4; ZNF165; IGFBP7; CXorf58; C15orf26;
ENSG00000224049; TCTEX1D2; TCEAL3; ENSG00000258940; DYNC2111; and
PKIG; and, wherein Group E consists of:
C8orf76; DNAJC22; ENSG00000250508; SEC23B; SLC35B1; KRT23; MRPL47; NIP7;
NDUFV2; KCTD14; GTF3C6; ISOC2; SAP30; HSBP1; PSMA5; ENSG00000262823;
SEC61B; TIMM17A; CLIC5; RPN1; LACC1; MRPL54; PSMB5; UCHL3; C14orf166;
C2orf47; PPP1R2; C5orf15; DNAJA1; HIGD1A; MIF; RAB9A; CASP7; POMP;
SERHL2; BCCIP; GRK5; UBB; PARK7; CHCHD2; FAR2; DNAJC12; NT5C3A;
UFM1; CDK7; CCDCl67; CCT2; MORF4L2; CALM2; C4orf19; PSENEN; HSPA8;
GTF2B; NDUFAB1; DAD1; SMS; KBTBD4; AGR3; GPR160; TCP1; PSMA3; STS;
LAMTOR5 COX17; UGCG; PSMA6; COX6A1; SLC41A2; HSP90B1; PDIA4; NXT2;
LACTB2; RFK; DYNLT1; COX7A2; BOLA3; MTFP1; FOLH1; PSMD10; NDUFB4;
MRPL39; C1orf122; MMADHC; SEC61G; NDUFB3; SSR4; NRIP1; ANG; WBP5
ABRACL; BIK; MRPS36; MOSPD1; SLIRP; MRPL13; CD24P4; ENSG00000113811;
LINC00493; SOD1; IGFBP6; PRDX4; ACTR6; SDF2L1; C19orf10; IL23A; BZW1P2;
CXCL17; and USMG5; and
wherein the airway dysfunction is COPD, asthma, bronchiolitis, bronchiectasis, lung transplant rejection, rheumatoid arthritis, graft versus host disease (GvHD), or autoimmune pneumonitis.